CompletedPhase 4

Effect of Rowachol on Prevention of Postcholecystectomy Syndrome

South Korea138 participantsStarted 2013-01

Plain-language summary

Postcholecystectomy syndrome (PCS) includes a heterogeneous group of diseases, usually manifested by the presence of abdominal symptoms following gallbladder removal. The pathogenesis of PCS has not been identified; therefore there is no consensus of medical treatment on PCS. The Action of Rowachol are to inhibit hepatic 3-hydroxy-3-methylglutaric acid(HMG)-coenzyme A(CoA) reductase, to inhibits cholesterol nucleation in bile from patients with cholesterol gallstones, and to promote biliary lipid secretion. The purpose of this study is to determine whether Rowachol is useful in the prevention of PCS and symptoms change after laparoscopic cholecystectomy

Who can participate

Age range18 Years – 84 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with pathologic diseases scheduled for laparoscopic cholecystectomy Exclusion Criteria: * Current immunosuppressive therapy * Chemotherapy within 4 weeks before operation * Radiotherapy completed longer than 4 weeks before operation * Inability to follow the instructions given by the investigator * Severe psychiatric or neurologic diseases * Drug- and/or alcohol-abuse according to local standards * Participation in another intervention-trial with interference of a primary or secondary endpoint of this study * Lack of compliance * Lack of informed consent

What they're measuring

the Number of the Participants Have Postoperative RUQ Pain

Timeframe: postoperative 3-month

Trial details

NCT IDNCT01765465

SponsorDongGuk University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-05

Results submitted2014-10-15

View on ClinicalTrials.gov More Postcholecystectomy Syndrome trials